In the healthy state, T cells are genetically programmed to survey and protect the body from infectious agents, environmental stressors, and malignancy. In the process of development and ...

Skin biopsy specimens of three lesions on her back were consistent with cutaneous T-cell lymphoma (CTCL). On physical examination, she had erythematous patches and plaques with ill-defined borders ...

Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interim Data from IIS Study Shows 75% Response Rate and Three ...

The US regulator has cleared Lymphir (denileukin diftitox) for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, resurrecting the ...

Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

"Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial" was originally created and published by ...

Soligenix (SNGX) announced interim results from the ongoing open-label, investigator-initiated study evaluating extended HyBryte treatment for ...